

# Myasthemia Gravis Forecast in 26 Major Markets 2017-2027

https://marketpublishers.com/r/M28D099466AEN.html

Date: March 2017

Pages: 92

Price: US\$ 6,150.00 (Single User License)

ID: M28D099466AEN

### **Abstracts**

Myasthenia Gravis (MG), also known as autoimmune myasthenia, is one of the most significant diseases affecting the neuromuscular junction. The disorder is caused by auto-antibodies that target components of the post-synaptic muscle endplate. This includes antibodies that target acetylcholine receptors (AChR), muscle-specific kinase (MUSK) and lipoprotein release protein 4 (LRP4). Please note that this module does not cover congenital MG forms.

This report provides the current prevalent population for Myasthenia Gravis across 26 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Ireland, Denmark, Netherlands, Norway, Sweden, Estonia, Croatia, Poland, Russia, Greece, Turkey, Japan, China, South Korea, Argentina, Brazil, Mexico, India and Australia) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Myasthenia Gravis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

MG often co-occurs with other autoimmune conditions including:

RA

MS



Ankylosing spondylitis
Psoriasis
Sjogren's syndrome
Ulcerative colitis
Crohn's disease
Other forms of AI

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

#### **REASON TO BUY**

Able to quantify patient populations in global Myasthenia Gravis market to target the development of future products, pricing strategies and launch plans.

Gain further insight into the prevalence of the subdivided types of Myasthenia Gravis and identify patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Provide a level of understanding on the impact from specific co-morbid conditions on Myasthenia Gravis prevalent population.

Identify sub-populations within Myasthenia Gravis which require treatment.

Gain an understanding of the specific markets that have the largest number of Myasthenia Gravis patients.







#### **Contents**

Introduction

Cause of the Disease

Risk Factors & Prevention

Diagnosis of the Disease

Variation by Geography/Ethnicity

Disease Prognosis & Clinical Course

Key Comorbid Conditions/Features Associated with the Disease

Methodology for quantification of patient numbers

Top-line Prevalence for Myasthenia Gravis

Classification of Myasthenia Gravis Patients

Serotype/Presence of Autoantibodies in Myasthenia Gravis

Comorbidities and Symptoms of Myasthenia Gravis patients

Abbreviations used in the report

Other Black Swan Analysis Publications

Black Swan Analysis Online Patient-Based Databases

Patient-Based Offering

Online Pricing Data and Platforms

References

**Appendix** 



# **List Of Figures**

# **LIST OF FIGURES**

MG at the neuromuscular junction



#### **List Of Tables**

#### LIST OF TABLES

Osserman criteria for severity staging of Myasthenia Gravis

Myasthenia Gravis Foundation of America criteria for severity staging

Prevalence of MG,total (000s)

Prevalence of MG, males (000s)

Prevalence of MG, females (000s)

MG patients by phenotype, total (000s)

MG patients by subtype, total (000s)

MG patients by severity, total (000s)

AChR seropositive MG, total (000s)

MUSK seropositive MG, total (000s)

LRP4 seropositive MG, total (000s)

MG patients with Thymoma, total (000s)

MG patients in Crisis, total (000s)

MG patients with Ptosis, total (000s)

MG patients with Dysphagia, total (000s)

MG patients with diplopia, total (000s)

MG patients with another autoimmune condition, total (000s)

Abbreviations and Acronyms used in the report

USA Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)

USA Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)

Canada Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)

Canada Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)

France Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)

France Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)

Germany Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)

Germany Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)

Italy Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)

Italy Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)

Spain Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)

Spain Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)

UK Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)

UK Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)

Ireland Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)

Ireland Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)

Denmark Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)



Denmark Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s) Netherlands Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s) Netherlands Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s) Norway Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s) Norway Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s) Sweden Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s) Sweden Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s) Estonia Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s) Estonia Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s) Croatia Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s) Croatia Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s) Poland Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s) Poland Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s) Greece Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s) Greece Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s) Turkey Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s) Turkey Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s) Argentina Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s) Argentina Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s) Brazil Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s) Brazil Prevalence of Myasthenia Gravis by 5-vr age cohort, females (000s) Mexico Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s) Mexico Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s) Japan Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s) Japan Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s) South Korea Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s) South Korea Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s) India Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s) India Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s) Australia Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s) Australia Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s) China Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s) China Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s) Russia Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s) Russia Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)



#### I would like to order

Product name: Myasthemia Gravis Forecast in 26 Major Markets 2017-2027

Product link: https://marketpublishers.com/r/M28D099466AEN.html

Price: US\$ 6,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/M28D099466AEN.html">https://marketpublishers.com/r/M28D099466AEN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:		
Last name:		
Email:		
Company:		
Address:		
City:		
Zip code:		
Country:		
Tel:		
Fax:		
Your message:		
	**All fields are required	
	Custumer signature	

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970